Business Today Eli Lilly's triple hormone drug retatrutide delivers 16.8% weight loss in phase 3 trial
The next generation of weight loss drugs is already in trials. Lilly's retatrutide delivered nearly 17% weight loss in 40 weeks, with patients still losing weight at the end of the trial.